Detalhe da pesquisa
1.
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
Clin Trials
; : 17407745231220661, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38205644
2.
Understanding and targeting erythroid progenitor cells for effective cancer therapy.
Curr Opin Hematol
; 30(4): 137-143, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052294
3.
Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer.
Int J Mol Sci
; 23(17)2022 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36077309
4.
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Int J Cancer
; 149(12): 2063-2074, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34319586
5.
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
Breast Cancer Res Treat
; 185(3): 639-646, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33219484
6.
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Breast Cancer Res Treat
; 189(1): 187-202, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34173924
7.
Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
Int J Mol Sci
; 21(13)2020 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32629782
8.
Primary and secondary breast angiosarcoma: single center report and a meta-analysis.
Breast Cancer Res Treat
; 178(3): 523-533, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31522347
9.
Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.
Ann Surg Oncol
; 26(7): 2191-2199, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30963401
10.
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
BMC Med Inform Decis Mak
; 19(1): 14, 2019 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658646
11.
High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer.
Int J Mol Sci
; 21(1)2019 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31905596
12.
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Breast Cancer Res Treat
; 170(2): 293-302, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29524062
13.
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
Breast Cancer Res Treat
; 168(3): 639-647, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29289986
14.
The role of skin ulceration in breast carcinoma staging and outcome.
Breast J
; 24(1): 41-50, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597587
15.
CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
J Immunol
; 193(10): 5327-37, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25320277
16.
Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients.
Cancers (Basel)
; 16(4)2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38398074
17.
Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
World J Gastroenterol
; 30(13): 1815-1835, 2024 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38659481
18.
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
Res Sq
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38746220
19.
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 16(6)2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539472
20.
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Cancer Med
; 13(5)2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38501219